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A B S T R A C T
This is a protocol for a Cochrane Review (Overview). The objectives are as follows:
Our objective is to produce an overview of the evidence in the Cochrane Database of Systematic Reviews for antepartum interventions
to prevent spontaneous preterm birth. We also aim to identify interventions with the potential to impact spontaneous preterm birth
and to make recommendations for future systematic reviews and clinical research.
B A C K G R O U N D
Each year approximately 15 million babies worldwide are born
before 37 weeks’ gestation (Blencowe 2012). In 2012, complica-
tions due to preterm birth led to the deaths of approximately one
million babies from all countries in the world, and infants who
survived risked substantial long-term disability (Lawn 2014). To
put that in to perspective, one million deaths in a year means that
2700 babies die every day - the equivalent of 5 jumbo jets full of
children. Globally, preterm birth is now the leading cause of death
for children under the age of five (WHO/UNICEF 2014; Liu
2015). The social and economic consequences of pretermbirth for
families and health systems are profound (Behrman 2007; Hodek
2011; Petrou 2011).
Most preterm births take place in the low- and middle-income
countries of Africa and South Asia, but pretermbirth rates in high-
income countries also continue to rise (March of Dimes 2012;
Blencowe 2013; Lawn 2014). Place of birth determines survival for
pretermbabies, with far highermortality rates at all gestational ages
in low- and middle-income countries (Blencowe 2012). Preterm
birth is a high priority for global maternal and newborn health
research. Researchers aim to improve the early detection of women
who are at risk, to identify causal pathways for preterm labour and
to develop new tocolytic drugs (Yoshida 2014; Yoshida 2016).
Preterm birth is ’indicated’ when continuation with the pregnancy
may put the mother or baby at risk of death. One-third of preterm
births is ’indicated’, where pregnant women have labour induc-
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tion or caesarean section before 37 weeks’ gestation to prevent
harm to mothers or babies from conditions such as pre-eclampsia
or intrauterine growth restriction. The remaining two-thirds of
preterm births are classified as ’spontaneous’, where births follow
unplanned preterm labour. This overview is concerned with pre-
vention of spontaneous preterm birth (sPTB) rather than indi-
cated pretermbirth (Blencowe 2013). Risk factors for spontaneous
pretermbirth range from individualmaternal factors to broader so-
ciodemographic factors, such asmaternal age or exposure to indoor
air pollution (Schempf 2007; Pope 2010; Bruce 2013; Amegah
2014). However, most spontaneous preterm births remain unex-
plained (Menon 2008). Behavioural, clinical and health-systems
level interventions each have the potential to reduce the sponta-
neous preterm birth rate and avert preterm-associated death and
disability (Requejo 2013).
Description of the condition
Preterm birth is defined as delivery before 37 weeks + 0 days’ ges-
tation (or 259 days) (Anonymous 1977). Standard subcategories
for reporting preterm birth data are: moderate to late preterm (32
weeks + 0 days to less than 37 weeks + 0 days’ gestation); very
preterm (28 weeks + 0 days to less than 32 weeks + 0 days’ gesta-
tion); and extremely preterm (less than 28 weeks + 0 days’ gesta-
tion) (Lawn 2010; March of Dimes 2012). How preterm birth is
defined has a profound impact on overall conclusions about the
efficacy of specific interventions. For example, March of Dimes
2012 argued that targeting late preterm births will produce the
biggest effect in addressing the survival gap between babies born
in low- or high-resource settings; they note that seven low- and
middle-income countries have halved the number of deaths in the
last 10 years, largely due to health systems interventions for the
80% of preterm babies considered ‘late preterm’ (32 weeks + 0
days to less than 37 weeks + 0 days’ gestation). Finally, we note
that preterm birth is itself a proxy outcome for a healthy neonate,
rather than an end of itself (Iams 2008).
Description of the interventions
Many interventions to prevent spontaneous preterm birth target
all pregnant women. These types of interventions are broad in
scope and may begin before pregnancy, such as folate supplemen-
tation, or during pregnancy, such as improved access to antenatal
care (Iams 2008). Other interventions target specific populations
of pregnant women considered to be at higher risk of spontaneous
preterm birth, such as women with multiple pregnancy or women
who smoke. This overview will include all interventions that could
be applied during pregnancy to women, regardless of risk factors.
Thus this overview will include interventions to prevent sponta-
neous preterm birth in women with co-morbid conditions (e.g.
diabetes, hypertension), women with recognised risk factors for
spontaneous preterm birth (short cervix, multiple pregnancy) and
interventions applied to all pregnant women where no specific risk
factors are known.
We will exclude interventions that target the following specific
cases.
1. Pregnant women exhibiting signs of preterm labour.
2. Pregnant women with preterm prelabour ruptured
membranes.
3. Pregnant women who have experienced a previous episode
of preterm labour in the current pregnancy.
This review is designed to identify interventions that are able to
reduce spontaneous preterm birth in an asymptomatic pregnant
population. Regular uterine contractions and membrane rupture
are part of a final common pathway of spontaneous preterm birth.
Pregnant womenwith symptoms of labour or premature prelabour
rupture of membranes (PPROM) will receive individualised man-
agement with specific interventions, but these interventions are
associated with a short timeframe to delivery and serve to im-
prove neonatal outcomes. Examples include magnesium sulphate
for neuroprotection, antenatal corticosteroids for respiratory dis-
tress syndrome or kangaroo care of the infant. Our review will not
consider such interventions. It is unclear whether prevention of
labour in women with PPROM or sPTB is of clinical benefit to
the neonate. Furthermore, labour or PPROM can be triggered by
infection, and maintaining the fetus in an infective environment
may cause the infant long-term neurological harm or short-term
risks of infection and sepsis (Lawn 2014). Finally, this overview
will not include interventions limited to the preconception period.
Eligible systematic reviews have tested the following categories
of interventions in randomised clinical trials (categories based on
Requejo 2013).
1. Clinical interventions (e.g. pharmacological interventions
such as progesterone or surgical procedures including cerclage).
2. Behavioural and nutrition interventions (e.g. dietary
education, exercise, micronutrient supplements, smoking
cessation programmes).
3. Health systems and policy interventions (e.g. screening for
infectious morbidity, vaccination, specialised clinics for multiple
births, reorganisation of antenatal care, workplace policies).
How the intervention might work
We will prepare a table of the interventions included in the
overview with information about how these interventions might
work. This overview aims tomap the evidence for all interventions
reporting preterm birth outcomes, whether the mechanism of as-
sociation with preterm birth is known or unknown. Both the UK
Health Technology Assessment report on preterm birth, Honest
2009, and the Born too Soon report, March of Dimes 2012, pro-
vide lists of interventions with potential to impact spontaneous
preterm birth. Bhutta 2014’s work onmaternal and neonatal mor-
tality and stillbirth provides a similar list of relevant interventions
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before and during pregnancy. We expect our overview will include
a similar list.
Why it is important to do this overview
Because both physiological and societal factors contribute to spon-
taneous preterm birth, there is a large literature reporting different
interventions as applied in different contexts. Mapping the effec-
tiveness of all interventions will provide an entry into the diverse
evidence on spontaneous preterm birth available in the Cochrane
Library (Becker 2011). A map of current Cochrane evidence will
also help clarify which interventions look promising for wider im-
plementation or for further research. We also aim to identify rel-
evant Cochrane systematic reviews in need of an update.
We intend for this overview to improve the care of pregnant
women. The rate of spontaneous preterm birth is steadily rising.
We do not fully understand the pathways leading to spontaneous
preterm birth, which has limited our progress in implementing
appropriate treatment strategies. It is likely that multiple inter-
ventions may lead to a reduction in spontaneous preterm birth.
For example, a low socioeconomic status or low body mass in-
dex (BMI) (both risk factors for spontaneous preterm birth) may
be modified by nutritional supplements, such as vitamin or pro-
tein provision. Likewise, targeting dental hygiene or screening for
asymptomatic bacteriuria in pregnancy may reduce the risk of in-
fection-related spontaneous preterm birth. Pregnancy represents
a significant life transition where women may have increased in-
teraction with health services. The World Health Organization
(WHO) recommends that pregnant women have at least four an-
tenatal visits that include screening for infection and knowledge of
pregnancy warning signs; these visits may also be an opportunity
to implement strategies to prevent spontaneous preterm births.
This review will identify promising areas of research that may en-
courage a ’multi-hit’ approach to reduce risk factors for sponta-
neous preterm birth in pregnancy, rather than a reactive approach
of treating women once they are symptomatic of labour.
Previous overviews of interventions to prevent preterm birth
are largely descriptive. lams and colleagues summarised evidence
for relevant interventions (Iams 2008). Piso and colleagues de-
scribed 56Cochrane systematic reviews of interventions to prevent
preterm birth and classified interventions by effectiveness (Piso
2014). Our overview will update these efforts and incorporate
quality assessment into the evidence summary.
This overview will also apply a recently agreed core outcome set
for preterm birth. A core outcome set states outcome domains
for use in future randomised clinical trials, systematic reviews and
overviews of reviews (van’t Hooft 2016). An outcome domain
represents one key aspect of a disease: it is the recommendation of
’what’ data should be collected by the trial rather than the ’how’ or
the specific measurement instrument (see the COMET website).
For example, mortality is one domain that may be associated with
spontaneous preterm birth, and the number of neonatal deaths
from birth to seven days is a measurement of this domain. The
core set for preterm birth states “any gestation of preterm birth”
as a domain, and preterm birth less than 37 weeks and other time
points are measurements of this domain.
O B J E C T I V E S
Our objective is to produce an overview of the evidence in the
Cochrane Database of Systematic Reviews for antepartum interven-
tions to prevent spontaneous pretermbirth.We also aim to identify
interventions with the potential to impact spontaneous preterm
birth and to make recommendations for future systematic reviews
and clinical research.
M E T H O D S
Criteria for considering reviews for inclusion
We have created a table with details of inclusion and exclusion
criteria for participants, interventions, comparisons, outcomes and
systematic reviews.
Eligibility Inclusion Exclusion
Participant level Population Pregnant women regardless of risk factors (in-
cluding women with co-morbid conditions)
Pregnant women with singleton or multiple
pregnancy
Healthcare providers
Pregnant women with acute signs of preterm
labour
Pregnant women with previous episode of
preterm labour in current pregnancy
Pregnant women with ruptured membranes
Intervention Behavioural, clinical or health systems interven-
tions
Any intervention not included in a Cochrane
review
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(Continued)
Comparison Intervention versus placebo or no treatment
Head to head comparisons of eligible interven-
tions (A versus B)
Dose comparisons
Comparisons outside the eligible population de-
fined above
Outcome Pretermbirth outcome [any gestational age (GA)
value] specified or reported (prespecified or post-
hoc)
Preterm birth outcome (any GA value) not spec-
ified or reported
Trial level Trial design Randomised clinical trials (including cluster or
quasi-randomised trials)
Any setting, language or year
Non-randomised designs
Review level Reviews Cochrane systematic reviews only
Trial search conducted within last 2 years or a
new search shows no new trials
Reviews scoring at least 4 on AMSTAR quality
assessment
Cochrane systematic reviews with network
meta-analysis
We will list reviews in need of an update (where
an updated search shows that relevant new trial
data are available)
We will evaluate each systematic review that we assess at the full-
text stage according to these inclusion and exclusion criteria. Sys-
tematic reviews eligible for inclusion in the overview with a search
date before 2014 will undergo further assessment as described be-
low (see Figure 1).
Search methods for identification of reviews
Because the objective of this overview is to produce a map of
evidence found in the Cochrane Database of Systematic Reviews,
only Cochrane systematic reviews will be eligible for inclusion. We
plan only to search the Cochrane Database of Systematic Reviews
(CDSR) (theCochrane Library) with a broad search strategy using
all terms that may possibly be used to describe preterm birth as an
outcome (see Appendix 1).
Data collection and analysis
Selection of reviews
Two overview authors will independently assess each title for in-
clusion, and will resolve any disagreements by discussion. We will
include review titles with relevant populations, interventions and
comparisons. Two overview authors will then independently assess
the full text of all systematic reviews that we include at the title
screening, and will resolve any disagreements by discussion. We
will exclude reviews published before 2014 and without preterm
birth data at the full-text assessment stage.
We will apply a decision tree to determine the eligibility of
Cochrane reviews published before 2014 with preterm birth data.
We will conduct new searches to determine the number of new
trials eligible for inclusion in an update of the systematic review.
If there are no new trials, we will include this pre-2014 systematic
review in the overview as per protocol. However, if the new search
for a pre-2014 systematic review identifies important randomised
clinical trials that may change the systematic review’s conclusions,
we will list the systematic review as in need of an update (see also
Figure 1).
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Figure 1. Decision tree to determine the eligibility of Cochrane reviews published before 2014
Wewill create ‘Characteristics of Reviews’ tables for both included
and excluded reviews that we assess at the full-text stage, including
the following information: author team and review title; review
objective; setting and important participant characteristics; inter-
vention; comparator; search date; number of included trials and
participants; and the review primary outcome domain with mea-
sure used. We will present a reason for exclusion where relevant.
Data extraction and management
For included systematic reviews, one overview authorwill indepen-
dently abstract data into a Microsoft Excel file. A second overview
author will check the data extraction. Wewill extract the following
characteristics from each included systematic review.
1. Number of trials included in the review.
2. Number of participants included in the review.
3. Participant characteristics.
4. For each prespecified outcome: the number of trials and
participants; the reported effect estimate and a corresponding
absolute risk reduction and number needed to treat (calculated
by the overview investigator, if we do not find it in the trial
report). Where available, we will also extract the GRADE
assessment and any relevant comments made in the systematic
review ’Summary of findings’ table regarding trial quality and the
risk of bias.
5. Any implications for practice or research published in the
review.
We will resolve any disagreements by discussion with the overview
author team. We will contact review and trial authors where nec-
essary to clarify data included in systematic reviews or to query
missing data.
Where multiple Cochrane reviews address the same clinical ques-
tion and are eligible for inclusion in the overview, we will system-
atically compare the systematic reviews for: search date, number
of trials and participants included in specific meta-analyses, ’Risk
of bias’ judgements for relevant trials, overall pooled effects of rel-
evant outcomes, and GRADE assessments of relevant outcomes.
We will attempt to avoid the duplication of evidence, and conse-
quent double-counting of trial data, by including only the most
current and inclusive systematic review on a given intervention.
We will make these decisions transparent in the main text and
in additional tables for the overview (Pollock 2014). We will not
exclude any systematic review solely on the basis of duplication of
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trial evidence; we anticipate several trials of preterm birth inter-
ventions will appear in multiple reviews.
Two overview authors will pilot the data extraction file, and we
anticipate that this work will lead to adaptation of the file.
Assessment of methodological quality of included
reviews
Methodological quality of included systematic reviews
One overview author will assess included systematic reviews with
the AMSTAR quality measurement tool, and a second overview
author will check these assessments for accuracy (Shea 2007; Shea
2009). The overview authors will resolve any discrepancies by
discussion. The AMSTAR tool consists of the following questions,
to be answered with either ‘yes’, ‘no’ or ‘unclear’.
1. Was an ’a priori’ design provided?
2. Was there duplicate study selection and data extraction?
3. Was a comprehensive literature search performed?
4. Was the status of publication (i.e. grey literature) used as an
inclusion criterion?
5. Was a list of studies (included and excluded) provided?
6. Were the characteristics of the included studies provided?
7. Was the scientific quality of the included studies assessed
and documented?
8. Was the scientific quality of the included studies used
appropriately in formulating conclusions?
9. Were the methods used to combine the findings of studies
appropriate?
10. Was the likelihood of publication bias assessed?
11. Was the conflict of interest stated?
One point is awarded for every question answered ‘yes’ for a high-
est possible score of 11. High quality reviews score 8 or higher;
moderate quality score 4 to 7; low quality systematic reviews score
3 or fewer ‘yes’ answers. We will exclude Cochrane systematic re-
views that do not meet the minimum quality standards of an AM-
STAR rating, which is at least 4. We will display the AMSTAR
assessments as an appendix to the review.
Quality of trial evidence included in reviews
Wewill not reassess the risk of bias for trials included in systematic
reviews. Where possible we will make use of the systematic review
authors’ GRADE assessments of relevant outcomes, as presented
in the ’Summary of findings’ tables of included systematic reviews.
The GRADE summary of findings in a Cochrane systematic re-
view incorporates an overall judgement of the risks of bias in the
specific trials contributing data to the pooled effect estimate for
each outcome displayed in the table. In addition to risk of bias,
for each outcome the GRADE assessment considers the following
domains: imprecision of effects (due to wide confidence intervals,
sparse data or both); unexplained inconsistency between trials (as
measured in the I² statistic value); indirectness (differences in the
population, intervention, comparison or outcome of trials); and
evidence of publication bias, where sufficient trials have been in-
cluded in the meta-analysis. Pooled evidence for randomised clin-
ical trials is downgraded by one for a ‘serious’ problem with any of
these domains. For some domains, evidence may be downgraded
twice if problems are ‘very serious’. GRADEpro Guideline Devel-
opment Tool (GDT) sums these downgrading decisions, and as-
signs the pooled estimate for each outcome a rating of either high,
moderate, low or very low (Guyatt 2008; GRADE handbook).We
will not exclude evidence of low or very low quality; the GRADE
of evidence is an important finding of the overview.
There are standard definitions given to aid the interpretation of
GRADE ratings, as follows.
1. High: further research should not alter our confidence in
evidence rated as of high quality.
2. Moderate: future research will likely impact our confidence
in moderate quality evidence and could change the estimates.
3. Low or very low: there is considerable uncertainty
surrounding the effect estimates considered to be of low or very
low quality, and further research will impact our confidence in
these effect estimates and change the estimates (Guyatt 2008;
Guyatt 2011a).
A GRADE assessment may be further translated into a summary
statement that incorporates the clinical importance of the effect,
for clarity, using the following guide.
Interpreting GRADE evidence assessments1
Level of evidence Important benefit/harm Less important benefit/harm No important benefit/harm or null effect
High Improves Improves slightly Little or no effect on (outcome)
Moderate Probably improves Probably improves slightly Probably little or no effect on (outcome)
Low May improve May improve slightly May have little or no effect on (outcome)
Very low We are uncertain whether (the intervention) improves (the outcome)
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1Santesso 2015. This guidance in interpreting GRADE is from an
oral presentation.
Data synthesis
Types of outcomes
We will only include Cochrane systematic reviews that report a
preterm birth outcome. We have chosen several additional clini-
cally important outcome measures to structure the overview. We
derived our outcome domains in part from the recent core out-
come set for preterm birth prevention (van’t Hooft 2016).
Effectiveness
1. Preterm birth: any gestational age reported.
2. Perinatal or neonatal mortality.
3. Offspring morbidity (infection and gastrointestinal,
respiratory or neurodevelopmental morbidity).
Safety
1. Any measure of safety, harm or side effect of treatment for
pregnant women or infants. We anticipate that overview authors
may need to make judgements about which specific outcome
measures should be included in this category.
Maternal satisfaction
1. Any measure of maternal satisfaction.
Economic costs
1. We will include cost-benefit, cost-effectiveness, cost
minimisation or cost of illness analyses. We will not include
proxy outcomes for costs such as length of stay.
Data synthesis and presentation
We will organise systematic review evidence for each of our pre-
specified overview outcomes. For each review, we will produce
a data synthesis table including the following key elements: sys-
tematic review characteristics, summary effect estimate and cor-
responding absolute risk reduction, GRADE assessment and an
overall effectiveness statement. One overview author will create
data synthesis tables and another overview author will check the
tables for accuracy. We will resolve any discrepancies by discussion
(see Table 1 for an example table based on Farquhar 2015).
The overview author team anticipate that the organisation and
structure of data synthesis tables will depend upon the available
data.We also expect that a planned pilot of the data synthesis table
with 10 priority reviews may require us to change the way we dis-
play evidence in the overview. We will organise the table format to
best communicate findings. Several overview authors have created
tables of evidence based on effectiveness, including categories such
as “What works”; “What might work”; “Effective interventions”;
“Promising interventions” or “Insufficent evidence” (Jones 2012;
Farquhar 2015; Lassi 2015; Welsh 2015). We describe essential
elements of the data synthesis table in further detail below.
1. Systematic review characteristics: including review title and
search date, intervention and comparator, and number of trials
and participants contributing data to the outcome in question.
2. Effect estimate (relative risk or odds ratio; absolute risk
reduction; number needed to treat): we will present the effect
estimates reported in the reviews. For improved understanding of
the systematic review evidence, overview investigators will also
calculate the absolute risk reduction (ARR) and number needed
to treat for an additional beneficial outcome or an additional
harmful outcome (NNTB;NNTH) for each outcome from the
relative risk or odds ratio presented in the systematic review (Akl
2011). Our prespecified outcomes are all dichotomous variables.
3. GRADE assessment: as described above, pooled effect
estimates will be imported into GRADEpro GDT and assessed
according to domains of risk of bias in included trials,
indirectness of evidence, imprecision of effects, heterogeneity
and publication bias.
4. Effectiveness statement: the overall effectiveness statement
applies standardised language to communicate the importance of
the findings of a systematic review. This “bottom-line statement”
will incorporate the GRADE assessment and the AMSTAR
rating together, to summarise all of the decisions made regarding
an intervention in a single, clear judgement (Ryan 2009; Ryan
2014). As suggested above, we expect that a pilot of the data
synthesis table will shape our final presentation of evidence,
including the effectiveness statement.
5. Recommendations for practice or research published in the
review.
Discussion and recommendations for research and clinical
practice
We aim to identify specific interventions with potential to impact
spontaneous pretermbirth.Our discussionwill highlightwherewe
have found high quality evidence of clinically-important effects.
We will list key Cochrane reviews in need of an update. Finally,
we will make recommendations for future systematic reviews and
clinical research.
Interactive ’Summary of findings’ tables
For selected key comparisons where there is sufficient evidence for
several of our clinically important outcomes, we will pilot use of
the interactive ’Summary of findings’ table (iSoF) to present sys-
tematic review evidence. A joint initiative between GRADE and
DECIDE, these iSoF tables provide a way to display layers of in-
formation for a given comparison and outcomes, including graph-
ical representations of NNTB/NNTH and confidence intervals,
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to improve understanding of the effects of health interventions
(see http://isof.epistemonikos.org/#/). The iSoF has been piloted
for use with systematic reviews rather than overviews, but we are
interested in creating an iSoF for our overview. To our knowledge,
no Cochrane overview to date has used an iSoF table.
Network meta-analysis
We will list relevant Cochrane network meta-analyses of interven-
tions for the prevention of preterm birth. There are few worked
examples for assessing the quality of network meta-analyses to es-
tablish confidence in results. Methodology for applying GRADE
criteria to the results of network meta-analysis emphasizes several
key components.
1. Rating the quality of the direct and indirect pairwise
evidence separately, and considering whether these estimates
differ (or are inconsistent).
2. Estimating the relative contribution of direct and indirect
estimates to the pooled effect estimate by creating a contribution
matrix.
3. Evaluating whether the transitivity (or similarity)
assumptions hold across comparisons (Guyatt 2011b; Puhan
2014; Salanti 2014).
The quality rating (high, moderate, low or very low) of each com-
parison in a network meta-analysis will vary, and readers may rea-
sonably prefer lower-ranked treatments with a higher GRADE as-
sessment of confidence (Puhan 2014). A GRADE assessment of
individual comparisons in a network meta-analysis can help dis-
tinguish between treatments of similar ranks by commenting on
the quality of the different trials contributing to these estimates.
We will pilot the application of GRADE criteria to included net-
work meta-analyses, with the aim to include GRADE assessments
of network meta-analyses in future updates of this overview.
Limitations of the overview and bias in the review process
A key limitation of our overview is the restriction of our search to
the Cochrane Library’s Cochrane Database of Systematic Reviews.
This method automatically imposes a language restriction and
eliminates non-Cochrane systematic reviews from possible inclu-
sion. We will also miss unpublished reviews and grey literature
(industry and governmental) reviews with this search strategy.
To minimise bias in the overview process, we will follow standard
reviewmethods includingmethods regardingduplication of effort,
resolution by discussion and exclusion of overview authors from
assessing their own systematic reviews or trials.Where an overview
author is also an author on an included systematic review, or an
author on a trial included in a systematic review, other members
of the overview author team will conduct data extraction, quality
assessment and data synthesis for that review.
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A D D I T I O N A L T A B L E S
Table 1. Data synthesis example
Review Comparison Outcome measure Number of trials/
participants
Effect estimate/
ARR/NNTB/
NNTH
GRADE
assessment
Effectiveness
statement
Recommendations for practice or research (published in the review)
Abbreviations:
ARR - Absolute Risk Reduction
NNTB - Number needed to treat for an additional beneficial outcome
NNTH - Number needed to treat for an additional harmful outcome
A P P E N D I C E S
Appendix 1. Search strategy
#1 preterm near birth*
#2 preterm near lab*r
#3 preterm near delivery
#4. pre-term near birth*
#5 pre-term near delivery
#6 premature near birth*
#7 pre-term near lab*r
#8 premature near delivery
#9 premature near lab*r
#10 MeSH descriptor: [Premature Birth] explode all trees
#11 MeSH descriptor: [Obstetric Labor, Premature] explode all trees
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
Limit to Cochrane reviews and protocols
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WH A T ’ S N E W
Date Event Description
24 January 2017 Amended Search strategy updated.
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